My watch list
my.chemeurope.com  
Login  

3,4-Diaminopyridine



3,4-Diaminopyridine
Systematic (IUPAC) name
3,4-Diaminopyridine
Identifiers
CAS number 54-96-6
ATC code  ?
PubChem  ?
Chemical data
Formula C5H7N3 
Mol. mass 109.13
Pharmacokinetic data
Bioavailability 30% [1],[2]
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status

Phase III

Routes Oral

3,4-Diaminopyridine is an experimental drug used in the treatment of Lambert-Eaton Syndrome. In Lambert-Eaton Syndrome, acetylcholine release is inhibited as antibodies meant to target characteristic cancers target Ca2+ channels on the prejunctional membrane instead. 3,4-Diaminopyridine works by blocking potassium channel efflux in nerve terminals so that action potential duration is increased. Ca2+ channels can then be open for longer time and allow greater acetylcholine release to stimulate muscle at end plate.

Product highlight

It has also been proposed for use in multiple sclerosis.[3]

See also

  • 4-Aminopyridine

References

  1. ^ AAEM Quality Assurance Committee. American Association of Electrodiagnostic Medicine. (2001). "Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthena gravis or Lambert-Eaton myasthenic syndrome: summary statement". Muscle Nerve 24: 1236-1238.
  2. ^ Lundh H, Nilsson O, Rosen I, Johansson S. (1993). "Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome.". Acta Neurol Scand 88: 136-140.
  3. ^ Judge S, Bever C (2006). "Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment". Pharmacol. Ther. 111 (1): 224-59. PMID 16472864.


 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "3,4-Diaminopyridine". A list of authors is available in Wikipedia.

Product highlight

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE